RT Journal Article
SR Electronic
T1 Polygenic Risk Prediction using Gradient Boosted Trees Captures Non-Linear Genetic Effects and Allele Interactions in Complex Phenotypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.09.21260288
DO 10.1101/2021.07.09.21260288
A1 Michael Elgart
A1 Genevieve Lyons
A1 Santiago Romero-Brufau
A1 Nuzulul Kurniansyah
A1 Jennifer A. Brody
A1 Xiuqing Guo
A1 Henry J Lin
A1 Laura Raffield
A1 Yan Gao
A1 Han Chen
A1 Paul de Vries
A1 Donald M. Lloyd-Jones
A1 Leslie A Lange
A1 Gina M Peloso
A1 Myriam Fornage
A1 Jerome I Rotter
A1 Stephen S Rich
A1 Alanna C Morrison
A1 Bruce M Psaty
A1 Daniel Levy
A1 Susan Redline
A1 the NHLBI’s Trans-Omics in Precision Medicine (TOPMed) Consortium
A1 Tamar Sofer
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.09.21260288.abstract
AB Polygenic risk scores (PRS) are commonly used to quantify the inherited susceptibility for a given trait. However, the standard PRS fail to account for non-linear and interaction effects between single nucleotide polymorphisms (SNPs). Machine learning algorithms can be used to account for such non-linearities and interactions. We trained and validated polygenic prediction models for five complex phenotypes in a multi-ancestry population: total cholesterol, triglycerides, systolic blood pressure, sleep duration, and height. We used an ensemble method of LASSO for feature selection and gradient boosted trees (XGBoost) for non-linearities and interaction effects. In an independent test set, we found that combining a standard PRS as a feature in the XGBoost model increases the percentage variance explained (PVE) of the prediction model compared to the standard PRS by 25% for sleep duration, 26% for height, 44% for systolic blood pressure, 64% for triglycerides, and 85% for total cholesterol. Machine learning models trained in specific racial/ethnic groups performed similarly in multi-ancestry trained models, despite smaller sample sizes. The predictions of the machine learning models were superior to the standard PRS in each of the racial/ethnic groups in our study. However, among Blacks the PVE was substantially lower than for other groups. For example, the PVE for total cholesterol was 8.1%, 12.9%, and 17.4% for Blacks, Whites, and Hispanics/Latinos, respectively. This work demonstrates an effective method to account for non-linearities and interaction effects in genetics-based prediction models.Competing Interest StatementB Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. All other co-authors declare no conflict of interest.Clinical TrialThis is not a clinical trial.Funding StatementMolecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome sequencing for "NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study" (phs000974.v4.p3) was performed at the Broad Institute Genomics Platform (3R01HL092577-06S1, 3U54HG003067-12S2). Genome sequencing for "NHLBI TOPMed: The Jackson Heart Study" (phs000964.v1.p1) was performed at the Northwest Genomics Center (HHSN268201100037C). Genome sequencing for the "NHLBI TOPMed: The Atherosclerosis Risk in Communities Study" (phs001211.v3.p2) was performed at the Broad Institute Genomics Platform (3R01HL092577-06S1) and the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201500015C, 3U54HG003273-12S2). Genome sequencing for "NHLBI TOPMed: Coronary Artery Risk Development in Young Adults Study" (phs001612.v1.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201600033I). Genome sequencing for "NHLBI TOPMed:Cleveland Family Study" (phs000954.v3.p2) was performed at the Northwest Genomics Center (3R01HL098433-05S1, HHSN268201600032I). Genomics sequencing for "NHLBI TOPMed: Cardiovascular Health Study" (phs001368.v2.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C, HHSN268201600033I). Genome sequencing for "NHLBI TOPMed: Hispanic Community Health Study/Study of Latinos" (phs001395.v1.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201600033I). Genome sequencing for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis" (phs001416.v2.p1) was performed at Broad Institute Genomics Platform (HHSN268201500014C, 3U54HG003067-13S1). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. The Genome Sequencing Program (GSP) was funded by the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Eye Institute (NEI). The GSP Coordinating Center (U24 HG008956) contributed to cross-program scientific initiatives and provided logistical and general study coordination. The Centers for Common Disease Genomics (CCDG) program was supported by NHGRI and NHLBI, and whole genome sequencing was performed at the Baylor College of Medicine Human Genome Sequencing Center (UM1 HG008898 and R01HL059367). ME, TS, and SR are supported by NHLBI grants R35HL135818 to SR. GMP is supported by R01HL142711 from the NHLBI. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant KL2TR002490 to LMR. PdV was supported by American Heart Association grant number 18CDA34110116 and NHLBI grant number R01HL146860. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mass General Brigham IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTOPMed freeze 8 WGS data are available by application to dbGaP according to the study specific accessions: FHS: phs000974.v4.p3, JHS: phs000964.v1.p1, MESA: phs001211.v3.p2, CARDIA: phs001612.v1.p1, CFS: phs000954.v3.p2, CHS: phs001368.v2.p1, HCHS/SOL: phs001395.v1.p1, ARIC phs001416.v2.p1. Study phenotypes are available from dbGaP from parent studies accession: FHS: phs000007.v32.p13, JHS: phs000286.v6.p2, MESA: phs000209.v13.p3, CARDIA: phs000285.v3.p2, CFS: phs000284.v2.p1, CHS: phs000287.v7.p1, HCHS/SOL: phs000810.v1.p1, ARIC: phs000090.v7.p1. https://dbgap.ncbi.nlm.nih.gov/